Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review

Keyphrases

• Insulin Therapy 100%
• Type 2 Diabetic Patients 100%
• Dipeptidyl peptidase-4 (DPP-4) 100%
• Insulin 42%
• Hemoglobin A1c (HbA1c) 42%
• Hypoglycemia Risk 42%
• Inhibitor Treatment 42%
• Placebo Treatment 28%
• Adverse Events 14%
• Diabetes 14%
• PubMed Database 14%
• MEDLINE 14%
• Glucose-lowering Drugs 14%
• Randomized Controlled Clinical Trial 14%
• Safety Profile 14%
• Baseline HbA1c 14%
• European Associations 14%
• Good Safety 14%
• Daily Dose 14%
• American Diabetes Association 14%
• Moderating Effect 14%
• Posters 14%
• Fasting Blood Glucose 14%
• Clinical Controlled Trial 14%
• Weight-neutral 14%
• Neutral Effects 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Dipeptidyl Peptidase IV Inhibitor 100%
• Insulin 100%
• Maturity Onset Diabetes of the Young 100%
• Hemoglobin A1c 57%
• Hypoglycemia 42%
• Controlled Clinical Trial 28%
• Placebo 28%
• Glucose 28%
• Adverse Event 14%